HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$122.50
+0.54%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$121.72
From 52W high+0.00%
Volume1.89M
Market cap$13.90B
P/E (TTM)34.8x
P/S (TTM)8.4x
Div yield—
Key dataOct 19, 2026
Open
$121.72
From 52W high
+0.00%
Volume
1.89M
Market cap
$13.90B
ValuationView details →
P/E (Fwd)
12.3x
EV/EBITDA
22.0x
P/E (TTM)
34.8x
RSI (14)
71.5
MomentumView details →
1D Return
+0.54%
YTD Return
+82.62%
SummaryUpdated Jun 1, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego-based biopharma technology platform company founded in 1998 that went public in 2004. The company has evolved from a traditional biotechnology firm into a specialized drug delivery technology platform, leveraging its proprietary ENHANZE technology to enable pharmaceutical companies to convert intravenous biologics into more convenient subcutaneous formulations. Over the past decade, Halozyme has transformed its business model from primarily developing its own drugs to licensing its platform technology to major pharmaceutical partners, creating a highly scalable and profitable royalty-based revenue stream.
Similar companies
Latest newsMore news →
Halozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.12d agoMerck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.12d ago